公开(公告)号：EP2185154A2

公开(公告)日：2010-05-19

申请号：EP08794839.4

申请日：2008-07-29

申请人： Schering Corporation ,  Pharmacopeia, LLC

发明人： FINE, Jay, S. ,  KIM, Seong, Heon ,  ANILKUMAR, Gopinadhan, N. ,  WONG, Michael, K. C. ,  ZENG, Qingbei ,  ROSENBLUM, Stuart, B. ,  KOZLOWSKI, Joseph, A. ,  SHAO, Yuefei ,  MCGUINNESS, Brian, F. ,  HOBBS,, Douglas, W.

IPC分类号： A61K31/497 ,  A61P11/00 ,  A61P11/06 ,  A61P17/00 ,  A61P17/14 ,  A61P19/02 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  A61K45/06

CPC分类号： A61K31/497 ,  A61K45/06 ,  A61K2300/00

摘要： The present application discloses a method of treating a CXCR3 chemokine receptor mediated disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, sarcoidosis, systemic lupus erythematosus (SLE), alkylosing spondylitis, fibrotic diseases, pulmonary fibrosis, alopecia areata, scleroderma, lichen planus erythematosus, discoid lupus erythematosus, dermatomyositis, Behcet's disease, Wegener's disease, atopic dermatitis, and graft-vs-host disease (GVHD) in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound having the general structure shown in Formula 1: Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein.